Friday’s Biggest Winners and Losers in the S&P 500
Friday was a positive day for the broad U.S. markets. Although all three major indexes had a slow start to the day each ended with a solid gain. Crude oil took another small step…
All Work
Chris Lange
What Analysts Are Saying About Cisco After Earnings
Cisco Systems reported its most recent quarterly results earlier this week and closed out its fiscal year. Analysts were fairly positive on the stock, with most giving the thumbs up for Cisco.
Why Applied Materials Earnings Beat Was Not Enough
Applied Materials released a mixed fiscal third-quarter financial results late on Thursday, and shares tumbled early Friday.
How Nordstrom Knocked It Out of the Park in Q2
Nordstrom reported better-than-expected quarterly results after the markets closed on Thursday, and shares rallied early Friday.
Why Nvidia’s Q2 Fell Short
Nvidia posted better-than-expected fiscal second-quarter earnings after the markets closed on Thursday, but weak guidance had shares down in Friday's premarket.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was a very positive day for the broad U.S. markets, with all three major indexes positing a solid gain on the day. Crude oil made a small recovery from a disastrous Wednesday. The…
Are Teva and Mylan Entering an EpiPen Price War to Zero?
Mylan has had a stranglehold on the market for EpiPen, but this is all changing after the FDA approved Teva for a generic version of it.
New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or…
What to Expect When Nvidia Reports After the Close
Nvidia is scheduled to release its fiscal second-quarter financial results after the markets close on Thursday.
Vertex Wins FDA Approval for Expanded Cystic Fibrosis Treatment
Vertex Pharmaceuticals shares saw a handy gain on Thursday after the FDA gave a nod to Vertex’s cystic fibrosis treatment.
Relocation for Work Reaches Historic Lows
In the 1980s, over one-third of job seekers were willing to move for a new position, but now this number is dramatically shrinking as new trends are emerging in the labor market.
How Nelson Peltz Is Pulling Off Another Solid Win for Wendy’s
Wendy's shares saw a handy gain on Thursday after the company announced that it accepted an offer to sell its ownership interest in Inspire Brands back to that company. This is a solid win…
Why Summit Therapeutics Is One of Thursday’s Top Biotechs
Summit Therapeutics shares made a solid gain early on Thursday after the firm announced that it was awarded an additional $12 million under its contract with the Biomedical Advanced Research and Development Authority.
How Cisco Dominated With Q4 Earnings
Cisco Systems released slightly better-than-expected fiscal fourth-quarter financial results after the markets closed on Wednesday.
How Macy’s Slipped Up in Q2
Macy’s released better-than-expected fiscal second-quarter financial results before the markets opened on Wednesday.
What to Expect When Walmart Reports Thursday
Walmart is scheduled to release its most recent quarterly results on Thursday before the markets open.
Why Casa Systems Is Wednesday’s Big Earnings Loser
Casa Systems second-quarter financial earnings beat and share buyback announcement were offset by soft guidance.
Is This the Quarter That Kills MoviePass?
Helios and Matheson Analytics, the parent company of MoviePass, is continuing to hemorrhage cash. The company is on the verge of collapse and its most recent update to investors is not helping its case.
What to Look For in Cisco’s Earnings Report
While Cisco did top Wall Street earnings estimates in its previous quarter, that didn’t seem to be enough for investors at the time.
What the FDA Has to Say About Regeneron’s Eylea
Regeneron Pharmaceuticals is facing some difficulty after it received an update from the FDA on Eylea (aflibercept) Injection in patients with wet age-related macular degeneration.